Within our fight against Covid-19, we have leveraged our expertise to generate antibody libraries across multiple discovery platforms in different species and applied a broad range of in vitro screening strategies and functional tests to gain
early insight into the functional characteristics of antibody candidates and epitope landscape. Parallel identification of potential developability liabilities using high throughput in silico profiling has guided the rational combination of
high value antibodies into cocktails that unlock synergistic effects, significantly boosting neutralization potency in pseudovirus-based assays. Subsequently, antibodies are examined for true developability profiles in vitro and subjected
to preclinical evaluation. Preliminary preclinical analysis of the antibody cocktails revealed strong antiviral effects against SARS-CoV-2 in both protective and therapeutic settings in a SARS-CoV-2 hamster model. Importantly, the antibody
cocktail is continuously subjected to specificity screenings against emerging SARS-CoV-2 mutants and show to date promising retained binding profiles against the S.African (B.1.351 lineage), Brazilian (P.1 lineage) and UK (B.1.1.7 lineage) strains.
ImmunoPrecise Antibodies (IPA) has more than 35 years of experience within the antibody discovery field and has developed into a global operating true single-source service provider for therapeutic antibody discovery and development programs to
a very broad range of (complex) targets in different disease areas. Amongst the end-to-end services are our comprehensive, species agnostic antibody discovery platforms such as B-cell Select and Phage Display which allows the selection of
a large and diverse antibody panel highly specific against the target of interest. Selected functional lead antibody candidates subsequently flow into IPA’s development and engineering platforms to minimize developability liabilities
and promoting clinical success.
In this webinar, attendees will learn about IPA’s comprehensive coverage facilitating opportunities for building plug-and-play therapeutic cocktails as part of a versatile portfolio for pandemic preparedness to address current and emerging
variants of SARS-CoV-2.
Key Learning Objectives:
- From target molecules to fully validated pre-clinical antibody lead molecules using IPA's complementary antibody platforms.
- IPA's antibody cocktail efficiently prevents and treats SARS-CoV-2 viral infection.
- IPA’s polytope approach focuses on treating emerging and future variants of SARS-CoV-2 to eventually eradicate the threat of SARS-CoV-2.
Debby Kruijsen, PhD
General Manager, IPA-EU Oss
ImmunoPrecise Antibodies (Europe) B.V.
Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.
She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe.
Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.
Ilse Roodink, PhD
Scientific Director, IPA-EU Oss
ImmunoPrecise Antibodies (Europe) B.V.
Ilse Roodink obtained a PhD in Medical Sciences at the Radboud University of Nijmegen, The Netherlands in 2009 and continued her research as a postdoctoral researcher developing an in vitro platform to isolate single domain antibodies specifically
recognizing tumor targets in its native conformation using phage display technology. In 2013, Ilse joined ImmunoPrecise Antibodies (Europe) as a scientist actively involved in phage display-oriented antibody discovery projects. She was promoted
to Scientific Director in 2019, where she is responsible for contract research project execution and management. Ilse is also actively involved in integration of innovative technologies supporting antibody characterization and engineering.
In 2019, Ilse was appointed as chairwomen of the scientific committee of Talem Therapeutics, an IPA company.
Cost: No Cost!